Greenwich Lifesciences Inc
NASDAQ:GLSI

Watchlist Manager
Greenwich Lifesciences Inc Logo
Greenwich Lifesciences Inc
NASDAQ:GLSI
Watchlist
Price: 24.98 USD 21.68% Market Closed
Market Cap: 346m USD

Greenwich Lifesciences Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Greenwich Lifesciences Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Greenwich Lifesciences Inc
NASDAQ:GLSI
EPS (Diluted)
-$1
CAGR 3-Years
-36%
CAGR 5-Years
-74%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$6
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$12
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
$14
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$42
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
24%
No Stocks Found

Greenwich Lifesciences Inc
Glance View

Market Cap
344.6m USD
Industry
Biotechnology

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is developing, GP2, a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.

GLSI Intrinsic Value
Not Available

See Also

What is Greenwich Lifesciences Inc's EPS (Diluted)?
EPS (Diluted)
-1.4 USD

Based on the financial report for Sep 30, 2025, Greenwich Lifesciences Inc's EPS (Diluted) amounts to -1.4 USD.

What is Greenwich Lifesciences Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-74%

Over the last year, the EPS (Diluted) growth was -75%. The average annual EPS (Diluted) growth rates for Greenwich Lifesciences Inc have been -36% over the past three years , -74% over the past five years .

Back to Top